K. Dallmeier

Single-dose YF17D-vectored Ebola vaccine candidate protects mice against both lethal surrogate Ebola and yellow fever virus challenge

This study develops a dual-target vaccine against Ebola and yellow fever viruses, showing it protects mice against both pathogens with a single dose.

Biodistribution and Environmental Safety of a Live-attenuated YF17D-vectored SARS-CoV-2 Vaccine Candidate

This study evaluates the safety and biodistribution of a YF17D-vectored SARS-CoV-2 vaccine candidate in hamsters, showing improved safety compared to parental YF17D.

The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters

This study shows that the omicron SARS-CoV-2 variant infects Syrian hamsters with significantly lower viral loads in the lungs compared to the D614G strain, with no detectable infectious virus.

Anti-SARS-CoV-2 human antibodies retaining neutralizing activity against SARS-CoV-2 B.1.1.529 (omicron)

The paper evaluates a panel of anti-SARS-CoV-2 monoclonal antibodies for neutralizing activity against SARS-CoV-2 delta and omicron variants, finding three mAbs retain activity, with mAb 3B8 showing potent neutralization against both.

A high-throughput neutralization assay for yellow fever serodiagnostics

This paper develops a high-throughput fluorescence-based assay (SNTFLUO) for detecting yellow fever neutralizing antibodies, validated against WHO standards and applicable for differential diagnostics.

Updated vaccine protects from infection with SARS-CoV-2 variants, prevents transmission and is immunogenic against Omicron in hamsters

This study shows an updated vaccine candidate provides full protection against multiple SARS-CoV-2 variants, prevents transmission, and induces neutralizing antibodies against Omicron in hamsters.

Spatial proteogenomics reveals distinct and evolutionarily-conserved hepatic macrophage niches

This study creates a spatial proteogenomic atlas of the liver across species, identifying conserved macrophage niches and their regulatory mechanisms.

Comparative infectivity and pathogenesis of emerging SARS-CoV-2 variants in Syrian hamsters

This study compares the infectivity and pathogenicity of SARS-CoV-2 variants B.1.1.7 and B.1.351 to early 2020 strains in Syrian hamsters, finding similar disease outcomes but stronger proinflammatory cytokine elevation in B.1.1.7 infections.

Nelfinavir markedly improves lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect

Nelfinavir reduces SARS-CoV-2-induced lung pathology in Syrian hamsters without affecting viral RNA or infectious titers.

The combined treatment of Molnupiravir and Favipiravir results in a marked potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model

This study shows that combining Molnupiravir and Favipiravir significantly enhances antiviral efficacy against SARS-CoV-2 in hamsters, reducing viral titers by 4.5 log10 and eliminating detectable virus in 60% of treated animals.

Identification of TMEM106B as proviral host factor for SARS-CoV-2

This study identifies TMEM106B as a host factor essential for SARS-CoV-2 infection and replication in human cells.

Hymenoptera associated eukaryotic virome lacks host specificity

The study identifies a diverse virome in honey bees and finds that many viruses are shared across Hymenoptera species, suggesting a lack of host specificity.

Antiviral treatment of SARS-CoV-2-infected hamsters reveals a weak effect of favipiravir and a complete lack of effect for hydroxychloroquine

This study evaluates the antiviral effects of favipiravir and hydroxychloroquine in SARS-CoV-2-infected hamsters, finding limited efficacy for both drugs.

A chimeric Japanese encephalitis vaccine protects against lethal yellow fever virus infection without inducing neutralizing antibodies